DOI: 10.21276/sajp.2018.7.2.3

Pages: 77-86

Vancomycin has been a predominant treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections for decades. Due to the resurgence of some resistant and intermediate strains to vancomycin, it is necessary to look for another alternative for continuing if not increased efforts to find novel strategies to combat MRSA infections. This review provides an overview of new conventional antibiotics registered within last three years as well as those that stayed strongly effective to MRSA despite their long usage, we also reviewed the alternative current investigational therapies in early clinical development (up to phase II clinical development) such as natural polyphenols, phage therapies, therapeutic antibodies and quorum sensing inhibitors. This developing portfolio of novel anti-staphylococcal drugs will hopefully provide us with additional and more efficient ways to combat MRSA infections in the near future and prevent us from running out of treatment options, even if new resistances arise.